{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:54:13Z","timestamp":1779144853523,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,15]]},"DOI":"10.1097\/qai.0b013e3182832578","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T12:27:06Z","timestamp":1356956826000},"page":"525-533","source":"Crossref","is-referenced-by-count":38,"title":["Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults"],"prefix":"10.1097","volume":"62","author":[{"given":"Frederick J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Pett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210131","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":". Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R2-8-20210131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":". Raltegravir with optimized background therapy for resistant HIV-1 infection.","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-8-20210131","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":". Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-8-20210131","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":". Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":". Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R6-8-20210131","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":". Long-term treatment with raltegravir or efavirenz combined with tenofoviremtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R7-8-20210131","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1517\/13543784.15.12.1507","article-title":"A historical sketch of the discovery and development of HIV-1 integrase inhibitors.","volume":"15","author":"Savarino","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R8-8-20210131","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":". Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"R9-8-20210131","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/QAD.0b013e32834f3507","article-title":". Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.","volume":"26","author":"Curran","year":"2012","journal-title":"AIDS"},{"key":"R10-8-20210131","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/QAD.0b013e328303be40","article-title":". Severe rhabdomyolysis associated with raltegravir use.","volume":"22","author":"Zembower","year":"2008","journal-title":"AIDS"},{"key":"R11-8-20210131","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAD.0b013e328334cc4a","article-title":". A case of rhabdomyolysis associated with raltegravir use.","volume":"24","author":"Dori","year":"2010","journal-title":"AIDS"},{"key":"R12-8-20210131","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jinf.2010.04.011","article-title":". Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution.","volume":"61","author":"Masia","year":"2010","journal-title":"J Infect"},{"key":"R13-8-20210131","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1258\/ijsa.2010.010246","article-title":". Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.","volume":"21","author":"Croce","year":"2010","journal-title":"Int J STD AIDS"},{"key":"R15-8-20210131","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1310\/hct1205-255","article-title":". Examination of noninferiority, safety, and tolerability of lopinavirritonavir and raltegravir compared with lopinavirritonavir and tenofoviremtricitabine in antiretroviral-naive subjects: the progress study, 48-week results.","volume":"12","author":"Reynes","year":"2011","journal-title":"HIV Clin Trials"},{"key":"R16-8-20210131","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":". Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.","volume":"11","author":"Eron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R18-8-20210131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jchromb.2007.06.032","article-title":". Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MSMS.","volume":"857","author":"Merschman","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R19-8-20210131","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":". ACCAHANHLBI clinical advisory on the use and safety of statins.","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R20-8-20210131","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy.","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"R21-8-20210131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1310\/hct1104-205","article-title":". Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.","volume":"11","author":"Lifson","year":"2010","journal-title":"HIV Clin Trials"},{"key":"R23-8-20210131","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":". Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.","volume":"52","author":"Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-8-20210131","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0002-9343(76)90327-2","article-title":"Steroid myopathy in connective tissue disease.","volume":"61","author":"Askari","year":"1976","journal-title":"Am J Med"},{"key":"R25-8-20210131","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":". Statin-associated myopathy with normal creatine kinase levels.","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"R26-8-20210131","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1758-2652-13-S4-P111","article-title":". Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study.","volume":"13","author":"Madeddu","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"R27-8-20210131","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/588794","article-title":". Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.","volume":"47","author":"Iwamoto","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R28-8-20210131","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0196-0644(89)80933-3","article-title":"Drug- and toxin-induced rhabdomyolysis.","volume":"18","author":"Curry","year":"1989","journal-title":"Ann Emerg Med"},{"key":"R29-8-20210131","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/clpt.2009.12","article-title":". Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.","volume":"85","author":"Wenning","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182832578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:58:44Z","timestamp":1620971924000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201304150-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,15]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182832578","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,15]]}}}